Document Detail

Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias.
MedLine Citation:
PMID:  7786839     Owner:  NLM     Status:  MEDLINE    
Intravenous cibenzoline was evaluated in 37 patients with acute supraventricular tachyarrhythmias and a ventricular rate > 120 beats/min. The presenting arrhythmia was atrial fibrillation in 15 patients, atrial flutter in 5, ectopic atrial tachycardia in 11, and paroxysmal atrioventricular (AV) junctional reentrant tachycardia in 6 patients. Intravenous cibenzoline was administered as a bolus given over 2 minutes, at a dose of 1 mg/kg in the first 26 patients and 1.2 mg/kg in the subsequent 11 patients, 15 minutes following failure of placebo (isotonic glucose). The results were evaluated 15 minutes after the intravenous injection. Restoration of sinus rhythm was obtained in 3 out of 6 patients with paroxysmal AV junctional tachycardia (50%) and in 7 out of 31 patients (23%) with atrial tachyarrhythmias (5 out of 15 patients with atrial fibrillation and 2 out of 16 patients with ectopic atrial tachycardia or atrial flutter). Five additional patients with atrial tachyarrhythmias had slowing of ventricular rate below 100 beats/min. Therefore, a satisfactory result, that is, restoration of sinus rhythm or slowing of ventricular rate, occurred in 15 patients (40.5%). Side effects were transient, including visual disturbance (one patient), asymptomatic widening of QRS complex (three patients), incessant reciprocating tachycardia (one patient), and acceleration of ventricular rate (eight patients), resulting in 1:1 flutter, with poor tolerance in two patients.(ABSTRACT TRUNCATED AT 250 WORDS)
P Bru; R Cointe; F Paganelli; P Ricard; S Lévy
Related Documents :
9510489 - The signal averaged p wave in atrioventricular block--evidence for abnormal atrial cond...
11060869 - Differentiating the ligament of marshall from the pulmonary vein musculature potentials...
11202249 - Passive-fixation j-shaped versus straight leads in atrial position: comparison of effic...
10498139 - Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary...
15785149 - Anticoagulation for atrial fibrillation in the elderly.
2212349 - Improved morphologic characterization of atrial septal aneurysm by transesophageal echo...
18784579 - Correlation between il-6 levels and the systemic inflammatory response score: can an il...
9713879 - Familiality of monocyte esterase deficiency in patients on continuous ambulatory perito...
15478149 - High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  9     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-07-27     Completed Date:  1995-07-27     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  85-8     Citation Subset:  IM    
Division of Cardiology, University of Marseille, School of Medicine, Hôpital Nord, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anti-Arrhythmia Agents / blood,  pharmacology,  therapeutic use*
Arrhythmias, Cardiac / drug therapy
Atrial Fibrillation / drug therapy
Blood Pressure / drug effects
Electrocardiography / drug effects
Heart Rate / drug effects
Imidazoles / blood,  pharmacology,  therapeutic use*
Injections, Intravenous
Middle Aged
Tachycardia, Supraventricular / drug therapy*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Imidazoles; 53267-01-9/cifenline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Elastic properties and Windkessel function of the human aorta.
Next Document:  Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy ...